FarmaKology-Lonza and Touchlight collaborate on end-to-end mRNA offering
MAIA Biotechnology, Inc.
MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types.
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
MannKind Corporation , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101) and is planning discussions with the U.S. Food and Drug Administration (FDA) regarding results and the ongoing clinical program.
Lonza and Touchlight collaborate on end-to-end mRNA offering
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced a collaboration with Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution. Through this collaboration, Lonza will have the ability to integrate an additional, differentiated source of DNA in its end-to-end offering to customers developing messenger RNA (mRNA) therapeutics and vaccines, while Touchlight can widen the channels through which customers can gain access to its novel doggybone DNA (dbDNA) technology.
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today a summary of its Type C Clinical meeting minutes with the U.S. Food and Drug Administration (FDA) relating to its lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with recurrent glioblastoma (GBM).
HealthBeacon in deal with American Pharmacists Association Foundation
Digital therapeutics company HealthBeacon has announced a new commercial partnership with the American Pharmacists Association Foundation. The Dublin headquartered firm develops products for managing injectable medications for people in the home.
Research & Study
Motion of DNA linked to its damage response, ability to repair itself
New reaction facilitates drug discovery
In Alzheimer’s, three drug candidates capture most of the industry's attention these days, and for good reason. They’re all in late-stage development and have the likes of Biogen, Eisai, Genentech and Eli Lilly backing them. But in this week’s episode, we step away from the big three. The Alzheimer’s Association found that there are 143 drugs in the pipeline. If fully enrolled, these trials would involve 50,575 people and more than 3.8 million participant weeks. We’ll dive into these details and more tidbits from AA’s report. And that’s not all. As we gear up to publish our annual Fierce 15 report honoring biotechs with the most exciting technologies, we’re also taking the time to look back at our 2012 class of Fierce 15. By now, several companies have fallen off the map, but many others were part of blockbuster deals or continue to plug away at their pipelines. We profile all of them, what they’ve been up to and what’s coming next.